This bill requires nursing homes in Louisiana to have a permanently installed generator or alternative power source on-site to ensure electricity during emergencies. Facilities must store fuel or other power generation materials either on-site or ensure they are delivered before any emergency occurs. The law updates existing regulations to mandate these backup power capabilities for nursing facilities. This change directly affects nursing home operators who must now maintain specific power infrastructure and fuel supplies. The legislation focuses on improving emergency preparedness without specifying particular outcomes or advocating for a particular viewpoint.
HB 732 allows Louisiana's Motor Vehicle Office to temporarily waive outstanding fees, fines, or license suspensions for up to 30 days when a person needs immediate access to life-sustaining medical treatment due to a life-threatening condition. It directly affects individuals with delinquent debt to the Motor Vehicle Office who provide documentation from a licensed physician or medical provider verifying the emergency. The bill requires the office to issue a written decision for each waiver and specifies that the temporary suspension does not forgive the underlying debt, though the commissioner may still reduce or eliminate the obligation at their discretion. This change takes effect upon gubernatorial approval or legislative override of a veto.
SB 43 establishes Louisiana's Psychedelic-Assisted Therapy Program within the Department of Health to fund clinical studies using psychedelic medications (like psilocybin) for treating opioid use disorders, co-occurring substance use disorders, and treatment-resistant mental health conditions. The program requires academic health centers to meet strict federal and state compliance standards - including FDA approval, safety protocols, and therapist qualifications - to conduct these studies. Eligible patients, including those with the specified conditions, may participate, and parishes can use opioid settlement funds to enroll residents. The bill mandates annual progress reports from participating centers and requires coordination with other states conducting similar research. This is a research-focused program, not a policy allowing general therapeutic use.
HB 1236 amends Louisiana laws governing pharmacy benefit manager reimbursements to establish a new payment formula based on claims data. This formula requires that reimbursement adjustments aim for a claim payment error rate of no more than two percent per drug. The bill also mandates that professional dispensing fees paid to pharmacists must be at least equal to the fee currently set by the Louisiana Department of Health for Medicaid. These changes directly affect pharmacy benefit managers and the state's Medicaid program by updating how they are compensated for dispensing medications.
SB 401 establishes a Prescription Drug Affordability Board within Louisiana's Department of Insurance to address rising prescription drug costs. The board would require drug manufacturers to report detailed pricing data - including production costs, research expenses, and marketing costs - and develop a list of "critical" drugs based on factors like public healthcare costs, usage, and availability of similar treatments. For drugs on this list, the board would set maximum allowable prices for sale in Louisiana, directly affecting manufacturers, pharmacies, and residents who purchase these medications. The bill aims to increase price transparency and control costs through data-driven price-setting, but it has not yet been enacted as it remains prefiling status.
HB 870 requires Louisiana health insurance issuers to immediately place cheaper generic drugs and biosimilars on more favorable formulary tiers (with lower out-of-pocket costs) when their wholesale acquisition cost is lower than the brand-name reference drug or product. Specifically, if a generic drug costs less than its brand-name equivalent at launch, insurers must cover it with better cost-sharing and cannot impose prior authorization, step therapy, or pharmacy restrictions that make it harder to access than the brand. The same rules apply to biosimilars that are cheaper than their reference biological products. This directly affects health insurance plans and enrollees seeking coverage for these cost-effective alternatives. The bill aims to reduce patient costs by mandating insurer action when cheaper, equivalent options become available.
HB 1199 mandates that health insurance plans cover genetic testing and treatments for SCN2A-associated medical conditions without imposing cost-sharing fees on members who are covered under their policy. The bill requires insurers to include these specific services in their coverage without charging patients a portion of the cost. This legislation directly affects individuals with SCN2A-related conditions and the health insurance providers who must adjust their benefit structures accordingly.
HB 1160 amends the laws governing rural physician licenses by updating specific terminology and clarifying the requirements for obtaining such licenses. The bill modifies the definition of a medical degree and adds language to ensure that licensing determinations are both approved and adopted through established administrative processes. It also changes the conditions under which a physician can be licensed, requiring them to meet a specific set of criteria rather than a single provision. These changes directly affect doctors practicing in rural areas and the state agencies responsible for issuing their medical licenses.
This bill, titled the Louisiana Clinical Trial Competitiveness and Patient Access Act, aims to support economic development by establishing a framework for clinical trials within the state. It directly affects healthcare providers, pharmaceutical companies, and patients by creating new provisions to enhance the competitiveness of clinical research in Louisiana. The legislation includes specific amendments that clarify the law does not override federal restrictions and expands the scope of protected protocols to include nonpublic ones. By adding these details, the bill seeks to provide clearer guidelines for conducting clinical trials while ensuring compliance with existing federal regulations.
This bill amends Louisiana law to require the Medicaid program to cover continuous glucose monitors for pregnant women with diabetes who use insulin more than twice daily or have experienced severe low blood sugar. The change specifically includes gestational diabetes, ensuring that eligible expectant mothers receive access to these monitoring devices as part of their treatment plan. By updating the state's Medicaid statutes, the legislation directly affects pregnant enrollees and the healthcare providers who administer their care.
